Paolo Tarantino shared on LinkedIn:

“Impressive to think at the journey of ADCs over the last five years.

Five years ago today, the only ADC approved for a solid tumor was T-DM1, approved for a limited subgroup of patients with metastatic breast cancer.

Five years later, we have 6 different ADCs approved, 2 more expected soon, indications for breast, lung, ovarian, gastric, cervical, urothelial cancer, an ADC approved for treating ANY type of tumor that overexpresses HER2, and 150+ new ADCs in active development.

And it’s only just started.”

Source: Paolo Tarantino/LinkedIn

Dr. Paolo Tarantino, MD researcher, holds positions at both the European Institute of Oncology in Milan, Italy, and the Dana-Farber Cancer Institute in Boston, MA, Specializing in breast cancer. Currently, Dr. Tarantino is pursuing an advanced research fellowship at Dana-Farber Cancer Institute and Harvard Medical School, concurrently working towards a PhD in clinical research at the University of Milan. His research focuses on exploring the HER2 oncoprotein, investigating the emerging HER2-low subgroup of breast tumors, and developing novel antibody-drug conjugates targeting every subtype of breast cancer. With a robust publication record exceeding 50 papers on breast cancer, he is recognized as a leading expert in the field. Dr. Tarantino’s dedication and innovative approach contribute significantly to the advancement of breast cancer treatment and research.